January 13, 2021
Authored and Edited by Shannon M. Patrick; Kara Specht; Elizabeth D. Ferrill
In ABS Global Inc., v. Cytonome/St, LLC, the Federal Circuit dismissed as moot an appeal of an inter partes review (IPR) upholding the patentability of some claims of U.S. Patent No. 8,529,161.
ABS’s appeal of the Board’s decision on the IPR followed a district court’s finding that ABS had not infringed the ’161 patent. Cytonome’s response to the appeal contained an affidavit disavowing its right to appeal the district court’s decision of noninfringement. Cytonome argued that ABS could not demonstrate injury in fact sufficient to support standing for the appeal because of its disavowal of further appeal on infringement.
The Federal Circuit found that Cytonome’s disavowal made it unlikely that Cytonome’s challenged behavior would reoccur, effectively finalizing the district court’s opinion. The Court then looked for evidence that ABS “engaged in or had concrete plans to engage in activities not covered by Cytonome’s disavowal.” ABS showed no record evidence indicating it was developing or had plans to develop an infringing product or would incur costs designing around the ’161 patent. While ABS argued its litigation history with Cytonome amounted to an injury in fact, the Court explained that prior litigation history alone is insufficient to establish a reasonable expectation that Cytonome would try to reassert the ’161 claims against ABS. The Federal Circuit, therefore, dismissed ABS’ appeal as moot.
Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.